ACON
Aclarion, Inc. · NASDAQ
- Sector Technology Services
- Industry Packaged Software
- Website aclarion.com
- Employees(FY) -
- ISIN US6551872012
Performance
+23.56%
1W
-21.85%
1M
-19.13%
3M
-54.09%
6M
-95.58%
YTD
-96.02%
1Y
Profile
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.
Technical Analysis of ACON 2024-12-27
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-03 02:45
- 2024-11-20 19:00
- 2024-11-14 04:00
- 2024-10-09 19:00
- 2024-09-26 18:57
- 2024-09-12 20:30
- 2024-09-11 18:57
- 2024-09-11 18:00
- 2024-09-11 01:00
- 2024-09-10 18:00
- 2024-09-09 18:57
- 2024-09-05 23:27
Aclarion Added to PRISM Emerging Medical Devices Index(Globenewswire)
- 2024-09-04 18:57
- 2024-08-28 18:57
- 2024-08-20 19:57
- 2024-08-14 21:48
- 2024-08-13 20:08
Aclarion Announces First Commercial Agreement in Michigan(Globenewswire)
- 2024-08-12 21:07
- 2024-07-08 19:00
- 2024-06-25 20:30
- 2024-06-24 20:30
- 2024-06-19 20:00
- 2024-06-17 19:00
- 2024-05-15 10:55
ACON Stock Earnings: Aclarion Reported Results for Q1 2024(Investorplace)
- 2024-04-28 21:00
- 2024-04-24 21:14
- 2024-04-22 20:00
- 2024-03-03 19:00
- 2024-02-27 02:22
Aclarion Announces Closing of $3.0 Million Public Offering(Globenewswire)
- 2024-02-25 20:15
Aclarion Announces Pricing of $3.0 Million Public Offering(Globenewswire)
Page 1 of 3
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.